You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,043,832

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,043,832

Title:	Method for determination of inflammatory bowel disease
Abstract:	The instant invention provides a method for the differential diagnosis of inflammatory bowel disease which comprises, determining the relative ratio of G0 oligosaccharide represented by formula (I): ##STR00001## to G2 oligosaccharide represented by formula (II): ##STR00002## wherein G represents galactose, M represents mannose, GN represents N-acetylglucosamine and F represents fucose in serum IgG oligosaccharide fraction obtained from a patient with inflammatory bowel disease or a patient with suspicion of inflammatory bowel disease, and discriminating inflammatory bowel disease based on the obtained ratio.
Inventor(s):	Miyoshi; Eiji (Suita, JP), Iijima; Hideki (Suita, JP), Shinzaki; Shinichiro (Suita, JP), Tsujii; Masahiko (Suita, JP), Hayashi; Norio (Suita, JP), Nakagawa; Takatoshi (Suita, JP), Kondo; Akihiro (Suita, JP), Taniguchi; Naoyuki (Suita, JP)
Assignee:	Osaka University (Suita-shi, Osaka, JP)
Application Number:	12/301,294
Patent Claims:	1. A method for the differential diagnosis of Crohn's disease or ulcerative colitis in patients having inflammatory bowel disease comprising, 1) isolating immunoglobulin G from the serum of a patient with Crohn's disease or ulcerative colitis, 2) releasing oligosaccharides from the immunoglobulin G, 3) determining the ratios of G0 oligosaccharide represented by formula (I): ##STR00005## to G2 oligosaccharide represented by formula (II): ##STR00006## to obtain G0/G2 ratios in the serum of the patient having Crohn's disease or ulcerative colitis and in the sera of healthy individuals, wherein G represents galactose, M represents mannose, GN represents N-acetylglucosamine and F represents fucose in serum IgG oligosaccharide fraction, and 4) generating a relative ratio by comparing G0/G2 ratio in the serum of the patient having Crohn's disease or ulcerative colitis with G0/G2 ratios in the sera of healthy individuals, 5) comparing the relative ratio of step 4) to a predetermined value, wherein the predetermined value is obtained by comparing G0/G2 ratio in the sera of patients having Crohn's disease or ulcerative colitis with G0/G2 ratios in the sera of healthy individuals, and 6) differentially diagnosing the patient as having Crohn's disease when the ratio of G0/G2 is higher than the predetermined value, and the patient is diagnosed as having ulcerative colitis when the ratio of G0/G2 is lower than the predetermined value. 2. The method according to claim 1, in which the higher G0/G2 value means the higher severity of inflammatory bowel disease in the patient. 3. The method according to claim 1, in which the lower G0/G2 value means the better prognosis of the patient with inflammatory bowel disease.

Details for Patent 8,043,832

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	12/12/2018	⤷ Try a Trial	2026-05-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.